PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 13, 2017New England Journal of Medicine1,180 citationsOpen Access

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

View Full Paper
JMJean‐Louis MasGDGeneviève DérumeauxBGB. Guillon

Structured PICO

Does PFO closure combined with antiplatelet therapy reduce stroke recurrence compared to antiplatelet therapy alone in patients with recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt?

P
Population
Patients with a recent cryptogenic stroke attributed to patent foramen ovale (PFO) with an associated atrial septal aneurysm or large interatrial shunt
I
Intervention
Patent foramen ovale (PFO) closure combined with antiplatelet therapy
C
Comparator
Antiplatelet therapy alone
O
Outcome
Stroke recurrencehard clinical

In patients with recent cryptogenic stroke and high-risk PFO features, PFO closure combined with antiplatelet therapy reduces the risk of stroke recurrence compared to antiplatelet therapy alone, albeit with an increased risk of atrial fibrillation.

Abstract

Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE ClinicalTrials.gov number, NCT00562289 .).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mas et al. (2017) studied this question.

synapsesocial.com/papers/69d56d5a75589c71d767d01ahttps://doi.org/10.1056/nejmoa1705915
Ask AI
Helpful
Bookmark
Share
View Full Paper